Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
Claus G Roehrborn1, Raymond C Rosen21Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA; 2New England Research Institutes, Watertown, MA, USAAbstract: Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in ag...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3c62a8f7c5e74916b124a7f817463211 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Claus G Roehrborn1, Raymond C Rosen21Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA; 2New England Research Institutes, Watertown, MA, USAAbstract: Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.Keywords: alfuzosin, lower urinary tract symptoms, benign prostatic hyperplasia, aging, cardiovascular system, sexual function |
|---|